List view / Grid view
6 August 2015 | By Victoria White
Scientists have made a discovery that brings them closer to a relapse prevention therapy based on selectively erasing dangerous drug-associated memories...
6 August 2015 | By Victoria White
Researchers from the University of Pennsylvania have identified a major genetic factor that keeps moles in their usual non-cancerous, no-growth state...
6 August 2015 | By Victoria White
MedImmune has entered into an exclusive clinical trial collaboration with Mirati Therapeutics to evaluate durvalumab in combination with mocetinostat...
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...
5 August 2015 | By Victoria White
Two research projects involving ADXS-PSA, which is being developed for prostate cancer, have been selected for 2015 Movember Foundation-PCF Challenge Awards...
5 August 2015 | By Victoria White
Pharmaxis and Synairgen are to collaborate to develop a selective inhibitor to the LOXL2 enzyme to treat idiopathic pulmonary fibrosis...
4 August 2015 | By Victoria White
MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...
4 August 2015 | By Victoria White
The oncology drug pipeline is far larger than any other therapy area with 6,484 products in active development across all indications...
4 August 2015 | By Victoria White
Researchers have used nanoparticles to breach the human airway mucus barrier of lung tissue - a finding that could lead to effective drug delivery systems...
4 August 2015 | By Victoria White
For vaccine development, financial barriers persist: pharma companies see high costs with limited market potential, and government support is lacking...
3 August 2015 | By Victoria White
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for immune cells, leaving them too drained to fight the disease...
3 August 2015 | By Victoria White
Prokarium has received new funding from SynbiCITE that will enable it to complete preclinical development of an innovative chlamydia vaccine...
3 August 2015 | By Victoria White
AstraZeneca and Isis Pharmaceuticals are to collaborate to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases...
31 July 2015 | By Oxford Global
In the run up to our 2nd Annual Drug Discovery USA Congress 2015, we spoke with Matthew Wagoner a discovery safety specialist from AstraZeneca, a confirmed speaker at the congress where he will talk about Bromodomain And ExtraTerminal (BET) Domain Inhibitors Induce A Loss Of Intestinal Stem Cells And Villous…
31 July 2015 | By Victoria White
Researchers have identified a new mechanism that the tumour suppressor protein p53 uses to trigger cell death via apoptosis...
